Compare Tango Therapeutics Inc. (TNGX) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs ProShares UltraPro S&P500 — how do they compare? Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B), while ProShares UltraPro S&P500 trades at $148.41 (market cap $5.68B). The key difference: ProShares UltraPro S&P500 is the larger of the two by market cap, and ProShares UltraPro S&P500 is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and ProShares UltraPro S&P500 for 30 Days on average.
| TNGX | UPRO | |
|---|---|---|
Market Cap | $3.75B | $5.68B |
Volume | 9,619,106 | 1,616,348 |
Sector | Health | Leveraged / Inverse |
52-Week High | $32.90 | $157.66 |
52-Week Low | $7.50 | $89.29 |
Typical Hold Time | 0 Days | 30 Days |
Enterprise Value | $2.77B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
UPRO trades at $155.38, showing minimal daily movement with a slight 0.05% decline. The technical outlook remains bullish with strong moving average signals, though oscillators indicate neutral momentum. Recent news highlights S&P 500 valuation concerns and expected profit growth deceleration from 35% in 2026 to 15% in 2027, creating mixed sentiment for this leveraged ETF.
As a leveraged S&P 500 ETF, UPRO's performance is tied to broader market movements. Current technical strength supports near-term upside potential, but elevated RSI levels and slowing earnings growth projections for the underlying index present headwinds. The ETF's leveraged structure amplifies both gains and losses, requiring careful risk management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
